Navigation Links
Study suggests blood test can help improve treatment outcomes for breast cancer patients
Date:5/15/2008

Washington, DC -- With the goal of tailoring cancer treatment for each individual, researchers at Georgetown University Medical Center today presented a study suggesting a simple blood test can help doctors more reliably assess treatment efficacy for patients with metastatic breast cancer.

It can take several weeks and sometimes months to determine if a particular cancer treatment is working because it can take that long to observe any significant radiographic changes in tumor size or appearance, says Minetta Liu, M.D., of Georgetowns Lombardi Comprehensive Cancer Center. Right now, we have to rely on radiology studies such as CT scans, ultrasound, and the like to determine whether or not there is disease progression. With this new blood test, we have another reliable tool that may allow us to determine much sooner if a therapy is ineffective so that we can change therapy earlier and potentially make more significant improvements in survival.

Using the FDA-approved CellSearch technology, researchers measured the number of circulating tumor cells (CTC) in blood collected from women with metastatic breast cancer. About one tablespoon of blood was collected every three to four weeks. The number of CTCs was correlated with disease response or progression as determined by standard radiology studies performed every 9-12 weeks. The women in the study received various treatments including chemotherapy, endocrine therapy, and combination therapy with a biologic agent.

A CTC count of five was used as the threshold, based on previous studies. There was a highly significant difference in the distribution of progression between two groups of patients defined by their CTC result. Seventy-one percent of patients who had a CTC greater than or equal to five had disease progression, and 66 percent of patients with a CTC count of less than five did not.

A CTC count of five or greater at the time of restaging was associated with a 5.32 fold increase in a patients chance of having disease progression compared to CTC counts of less than five, explains Liu. CTC assessments should be used as a surrogate marker for treatment efficacy and disease responsiveness. Changes in CTC results from less than five to greater than or equal to five over time may herald disease progression.

Liu adds that the CTC assay is a more reliable means of assessing treatment response than the traditional tumor markers currently in use.

We have a follow-up study underway that evaluates CTC results within the framework of a randomized clinical trial to eliminate potential variability from the treatment administered, says Liu, the national principal investigator of the new trial. Liu and her colleagues believe a study with the same therapies would offer even stronger evidence for routine use of CTC in patients with metastatic breast cancer.

We have many treatment options for advanced breast cancer. The key is to find the most effective therapy for each patient. It shouldnt take months to figure that out, she concludes.


'/>"/>

Contact: Karen Mallet
km463@georgetown.edu
414-312-7085
Georgetown University Medical Center
Source:Eurekalert

Related medicine news :

1. Study takes a step toward better defining fatigue
2. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
3. Study finds parents use cough medicines on under-2s despite the warnings
4. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
5. Study Supports Popular HIV Drug Regimen
6. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
7. Study shows that prostate cancer increases the risk of bone fracture
8. Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer
9. Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds
10. New Study: Texas Seniors 4th Hardest-Hit from Proposed Bush Administration Medicare Cuts
11. Study Finds More Than One in Two Women are Too Embarrassed to Discuss Vaginal Discomfort With Their Doctors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... Y. (PRWEB) , ... February 27, 2017 , ... POUGHKEEPSIE, ... ILADS ) has disclosed that despite scientific studies, the Center for Disease Control ( ... chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into a single ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... an upgrade to the company's Yelp listing. Bay Area residents struggling from thinning ... as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... lab became the world’s first to be ISO/IEC 17025:2005 INAB accredited for Der ... , ISO/IEC 17025:2005 is the globally recognised standard that sets out requirements for ...
(Date:2/26/2017)... ... February 26, 2017 , ... ... scheduling, and reporting for healthcare organizations. This comprehensive and customizable solution empowers ... process. StaffBridge technology improves staffing efficiency, maximizes resource allocation, collects critical reporting ...
(Date:2/25/2017)... ... February 25, 2017 , ... FCPX users now have the ability to ... Studios. With ProSharpen Color users have total control over sharpening amount, sharpening radius, threshold, ... With color spectrum tools users can visually see the color range effected with ease ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... , Feb. 27, 2017  Interpace Diagnostics Group, ... provides clinically useful molecular diagnostic tests and pathology services, ... presented at the upcoming United States ... held March 4-10, 2017 in San Antonio, ... a review of data from the Company,s extensive experience ...
(Date:2/27/2017)... Fla. , Feb. 27, 2017 ... focused on developing cerebral embolic protection devices for ... the FDA,s Circulatory System Devices Panel that convened ... need for cerebral protection following transcatheter aortic valve ... by this FDA panel support the need for ...
(Date:2/27/2017)... 2017  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the ... focused on tissue protection, repair and regeneration, today ... Ltd., received a positive response from the U.S. ... for RGN-137 to treat epidermolysis bullosa ("EB"). RGN-137 ... Thymosin beta 4 ("Tß4") as the active pharmaceutical ...
Breaking Medicine Technology: